Waters and Rosetta Biosoftware Collaborate to Advance the Analysis of Complex Biological Mixtures
News May 31, 2007
Specifically, the companies will work together to ensure that Rosetta Biosoftware's solution for protein expression data management and analysis, the Rosetta Elucidator® system, will process and analyze mass spectrometry data generated from the Waters® Q-Tof Premier™ and Synapt™ High Definition Mass Spectrometry™ (HDMS) Systems.
The collaboration will focus on developing software interfaces between the Elucidator system and Waters instrument systems that will give scientists the capability to perform comprehensive qualitative and quantitative profiling of complex biological mixtures.
"We are pleased to enable compatibility between the Elucidator system, and our innovative UPLC/MSE data acquisition methods and instruments," said Tim Riley, Vice President and Managing Director – Pharmaceutical Business Operations, Waters Division.
"This collaboration will enable more of our customers to take advantage of our advanced mass spec technologies to comprehensively analyze the results of their most demanding experiments," Riley added.
"Collaboration with Waters will allow us to rapidly adapt to advances in Waters instrument technology, ensuring that our customers have continued access to a robust end-to-end solution," said Yelena Shevelenko, Vice President and General Manager of Rosetta Biosoftware. "The streamlined integration will improve research productivity and provide solutions for a broader scientific audience."
The Waters Corporation and Rosetta Biosoftware will be exhibiting their latest technologies at the 55th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry, June 3 - 7, 2007 in Indianapolis, Indiana.
Test For Designer Drugs Could Help Treat Overdose PatientsNews
Medical professionals are scrambling to meet the growing demand for emergency room treatment, but they’re hampered by the lack of a quick and easy test to screen patients for “designer” drugs. Chemists have now developed such a test and are refining it with the hope that hospitals could eventually use it to choose the appropriate treatment.READ MORE
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
Comments | 0 ADD COMMENT
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018